A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
The recently unveiled conjugate DS3610a is to start phase 1.
After menin, the company tries again with farnesyl transferase.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
The companies clash over survival curve similarities – and differences.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
After ZW171's exit, ZW251 enters the clinic.
